| Symbol | FHTX |
|---|---|
| Name | FOGHORN THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 500 TECHNOLOGY SQUARE,SUITE 700, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 586-3100 |
| Fax | — |
| — | |
| Website | https://www.foghorntx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001822462 |
| Description | Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. Additional info from NASDAQ: |
Lynch Thomas J. Jr. 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000007
Read moreDuty Stuart 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000007
Read moreBiller Scott 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000004
Read moreGallagher Neil 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000004
Read moreMendelsohn Michael 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000004
Read moreSMITH IAN F 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000005
Read moreGILL SIMBA 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000005
Read moreCole Douglas G. 🟢 acquired 28.0K shares (1 derivative) of Foghorn Therapeutics Inc. (FHTX) at $4.08 Transaction Date: Jun 24, 2026 | Filing ID: 000005
Read more(99% Neutral) FOGHORN THERAPEUTICS INC. (FHTX) Announces Regulatory Update
Read moreFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | Phase2 | Small Cell Lung Cancer | Not_Yet_Recruiting | 2026-09-04 | 2029-01-31 | ClinicalTrials.gov |
| NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myelo… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2026-02-03 | 2030-02-01 | ClinicalTrials.gov |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tum… | Phase1 | Advanced Synovial Sarcoma | Terminated | 2021-08-17 | 2023-12-04 | ClinicalTrials.gov |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematol… | Phase1 | Advanced Hematologic Malignancy | Active_Not_Recruiting | 2021-06-14 | 2027-06-01 | ClinicalTrials.gov |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Phase1 | Metastatic Uveal Melanoma | Terminated | 2021-05-11 | 2023-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| FHD-286 | Other | Phase PHASE1 | Metastatic Uveal Melanoma | TERMINATED | NCT04879017 |
| FHD-609 | Other | Phase PHASE1 | Advanced Synovial Sarcoma | TERMINATED | NCT04965753 |
| Decitabine | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| Low Dose Cytarabine | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | Other | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| FHD-286 | Other | Phase PHASE2 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07551635 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| FHD-609 | DRUG | Phase PHASE1 | Advanced Synovial Sarcoma | TERMINATED | NCT04965753 |
| Decitabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |
| Low Dose Cytarabine | DRUG | Phase PHASE1 | Advanced Hematologic Malignancy | ACTIVE_NOT_RECRUITING | NCT04891757 |
| FHD-286 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT07283094 |